Figure 3.
Kaplan‐Meier estimates of the probability of overall survival among long‐term survivors with progression‐free survival ≥ 12 mo, according to nivolumab administration duration
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.